BiotechTube

Abciximab

Phase 1/2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carotid Stenosis

Conditions

Carotid Stenosis

Trial Timeline

— → —

NCT ID
NCT00178451

About Abciximab

Abciximab is a phase 1/2 stage product being developed by Eli Lilly for Carotid Stenosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00178451. Target conditions include Carotid Stenosis.

What happened to similar drugs?

3 of 6 similar drugs in Carotid Stenosis were approved

Approved (3) Terminated (1) Active (2)
🔄RosuvastatinAstraZenecaPhase 3
✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
✅EvolocumabAmgenApproved
❌Rimonabant + Placebo (for Rimonabant)SanofiPhase 3
🔄Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00178451Phase 1/2Withdrawn
NCT00440895ApprovedCompleted
NCT00440778ApprovedCompleted
NCT00420030ApprovedCompleted
NCT00354406ApprovedCompleted
NCT00167765Phase 3Terminated
NCT00126139Phase 3Terminated
NCT00073372Phase 3Terminated
NCT00169819ApprovedCompleted

Competing Products

9 competing products in Carotid Stenosis

See all competitors
ProductCompanyStageHype Score
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
39
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
43
simvastatin + placeboMerckPre-clinical
26
Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + SimvastatinMerckPhase 2
35
EvolocumabAmgenApproved
39
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Rimonabant + Placebo (for Rimonabant)SanofiPhase 3
32
Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3
37